The QualityStocks Daily Tuesday, May 30th, 2023

Today's Top 3 Investment Newsletters

StockEarnings(ATTO) $2.6600 +82.19%

360wallstreet(ACON) $1.0500 +77.97%

PennyStockProphet(WLDS) $1.8400 +57.27%

The QualityStocks Daily Stock List

T2 Biosystems (TTOO)

MarketBeat, StockMarketWatch, Schaeffer's, Marketbeat.com, BUYINS.NET, StreetInsider, TopPennyStockMovers, QualityStocks, Barchart, TraderPower, TradersPro, Stock Gumshoe, MarketClub Analysis, Daily Trade Alert, InvestorPlace, ProTrading Research, The Stock Dork, StockEarnings, Trades Of The Day, The Street, Trading Concepts, Buzz Stocks, Investing Daily, Investing Futures, Profitable Trader Authority, StockOnion, Wealth Insider Alert, OTCtipReporter, Penny Pick Finders, PennyStockProphet, PennyStockScholar, PoliticsAndMyPortfolio and Street Insider reported earlier on T2 Biosystems (TTOO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

T2 Biosystems Inc. (NASDAQ: TTOO) (FRA: 3T2) is an in vitro diagnostics firm that is focused on the development of product candidates and diagnostic products internationally as well as in the United States.

T2 Biosystems Inc. operates in the U.S. and was established on April 27, 2006 by Ralph Weissleder, W. David Lee, Lee Josephson, Tyler Jacks, Robert S. Langer Jr. and Michael J. Cima. The firm has its headquarters in Lexington, Massachusetts. The company has collaboration agreements with Allergan Sales LLC and Canon U.S. Life Sciences Inc. to develop a detection diagnostic test panel to identify Lyme disease and other pathogen species.

T2 Biosystems Inc. is part of the medical equipment and supplies manufacturing industry and provides diagnostic instruments, like the T2 Magnetic Resonance technology for the detection of pathogens, biomarkers and other abnormalities in unpurified sample types from patients (the samples include urine, cerebral spinal fluid, sputum, saliva, serum, plasma and whole blood).

T2 Biosystems Inc.’s products include an instrument used to detect pathogens that are linked to Lyme disease and sepsis dubbed the T2Dx Instrument; a penal that is used to identify Candida species from whole blood that is known to cause sepsis, called T2Candida Panel and a multiplex diagnostic panel that can detect different bacterial pathogens linked to sepsis dubbed T2Bacteroa Panel. In addition to this, the firm also provides a coronavirus molecular diagnostic test called T2SARS-CoV-2 Panel and a panel used for the sensitive and early detection of carbapenemase-resistance markers called the T2Resistance Panel.

T2 Biosystems Inc. announced recently that its T2SARS-CoV-2 Panel can detect different covid-19 strains including the Brazil, South Africa and UK variants. With the pandemic still plaguing most regions in the world, the tool will be highly reliable and useful for many healthcare systems.

T2 Biosystems (TTOO), closed Tuesday's trading session at $0.1347, up 42.389%, on 233,760,773 volume. The average volume for the last 3 months is 1.799M and the stock's 52-week low/high is $0.0915/$15.00.

Corvus Pharmaceuticals (CRVS)

MarketClub Analysis, MarketBeat, StreetInsider, StockMarketWatch, Schaeffer's, Zacks, QualityStocks, BUYINS.NET, TraderPower, TopPennyStockMovers, Trades Of The Day, TradersPro, The Street, PoliticsAndMyPortfolio and Penny Stock reported earlier on Corvus Pharmaceuticals (CRVS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) (FRA: C17) is a clinical stage biopharmaceutical firm that is focused on developing and commercializing immune-oncology therapies.

The firm has its headquarters in Burlingame, California and was incorporated in 2014, on January 27th by Joseph J. Buggy, Peter A. Thompson and Richard A. Miller. It operates as part of the pharmaceutical and medicine manufacturing industry, under the health care sector.

The company is party to a strategic collaboration with Angel Pharmaceuticals Ltd, which entails developing its pipeline of investigational medicines. The company serves consumers in the United States.

The enterprise’s product pipeline comprises of an oral small molecule A2A receptor antagonist dubbed CPI-444, which is undergoing a phase 2 clinical trial for adenosine; a covalent ITK inhibitor known as CPI-818, which is in a phase 1 clinical trial evaluating its effectiveness in treating individuals with malignant T-cell lymphomas; and an anti-CD73 monoclonal antibody dubbed CPI-006, which is undergoing a phase 3 trial for coronavirus as well as a phase 1 trial that activates different immune cells and inhibits adenosine production. The enterprise’s pre-clinical stage products include an adenosine A2B receptor antagonist dubbed CPI-935, which is indicated for fibrosis prevention; and an antibody known as CPI-182, which has been designed to block myeloid derived suppressor cells as well as neutrophil migration and function.

An Investigational New Drug application submitted by the company’s partner Angel Pharmaceuticals for their CPI-818 formulation has been accepted by the China National Medical Products Administration Center for Drug Evaluation. The success and approval of the formulation for use in treating relapsed/refractory T-cell lymphomas will benefit patients as well as bring in more revenues and investors into both companies.

Corvus Pharmaceuticals (CRVS), closed Tuesday's trading session at $3.09, up 18.8462%, on 1,805,107 volume. The average volume for the last 3 months is 782,442 and the stock's 52-week low/high is $0.607/$3.70.

Applied Optoelectronics (AAOI)

StocksEarning, Zacks, MarketBeat, MarketClub Analysis, Schaeffer's, InvestorPlace, StockEarnings, StreetInsider, The Street, Barchart, StockMarketWatch, Kiplinger Today, Daily Trade Alert, The Online Investor, BUYINS.NET, The Best Newsletters, Profit Confidential, Trades Of The Day, Investment House, QualityStocks, Hit and Run Candle Sticks, Investment U, InvestmentHouse, Investopedia, Louis Navellier, The Stock Dork, TraderPower, Rick Saddler, Marketbeat.com, Investing Signal, Investing Futures, INO.com Market Report, FreeRealTime, Short Term Wealth and Market Intelligence Center Alert reported earlier on Applied Optoelectronics (AAOI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Applied Optoelectronics Inc. (NASDAQ: AAOI) (FRA: A59) is focused on designing, manufacturing and selling different fiber-optic networking products.

The firm has its headquarters in Sugar Land, Texas and was incorporated in 1997, on February 28th by Chih Hsiang Lin. It serves consumers across the globe, with a focus on the United States, the People’s Republic of China and Taiwan.

The company operates in Taipei, Ningbo and Taiwan and China, via its wholly owned subsidiary known as Prime World International Holdings Limited. This subsidiary operates a branch in Taipei, Taiwan, which is mainly involved in the manufacture of transceivers. It also conducts research and development activities for its transceiver products. In addition to this, the company has a research and development facility in the state of Georgia. Its customers include Microsoft, Facebook, Amazon, Cisco Systems and Arris Group. The company generates the majority of its revenue from Taiwan and China.

The enterprise uses its Molecular Beam Epitaxy fabrication process to manufacture its products, which include transceivers, transmitters, turn-key equipment and optical devices like photodiodes, subassemblies and laser diodes, as well as distribution, node and headend equipment, which allow for faster connections. It sells its products through indirect and direct sales channels. The enterprise serves the telecom equipment manufacturer, fiber-to-the-home, Cable Television Broadband and internet data center markets.

The firm recently released its financial results for the third quarter of 2021, with its CEO noting that they had observed an improvement in Datacom. Currently, the firm is focused on growing its CATV business.

Applied Optoelectronics (AAOI), closed Tuesday's trading session at $2.3, up 21.0526%, on 783,297 volume. The average volume for the last 3 months is 223,179 and the stock's 52-week low/high is $1.48/$4.00.

PyroGenesis Canada (PYR)

QualityStocks, MarketClub Analysis, Trades Of The Day, StocksEarning and Schaeffer's reported earlier on PyroGenesis Canada (PYR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

PyroGenesis Canada Inc. (NASDAQ: PYR) (TSE: PYR) (FRA: 8PY) is an environmental solutions firm that is focused on designing, developing, manufacturing and commercializing advanced plasma systems and processes.

The firm has its headquarters in Montreal, Canada and was incorporated in 1991. The firm has three companies in its corporate family and serves consumers around the globe. It operates through the Mexico, Asian, Europe, United States and Canada geographical segments.

The enterprise provides a process to produce high purity solar-grade and metallurgical grade silicon from quartz known as Purevap; a sustainable process that improves metal recovery from dross targeting known as Drosrite; and a silicon reactor that’s been designed to transform silicon into spherical silicon nanowires and nanopowders for use in Li-ion batteries known as the Purevap Nano silicon reactor. It also offers plasma torches which include SPT plasma torches for use in refrigerant destruction and other substances; and APT high-powered plasma torches to replace fossil fuel burners. In addition to this, the enterprise provides plasma resource recovery systems for waste-to-energy and land-based waste destruction applications; plasma arc chemical warfare agents; plasma arc waste destruction systems for waste destruction on ships; and plasma arc vitrification and gasification. The enterprise serves the environmental, oil and gas, 3D printing, mining, metallurgical and defense industries.

The company recently launched a new zero-carbon emission hydrogen production technology which produces environmentally-friendly hydrogen. This move positions the company for significant growth in the market, especially with the consumption of zero-carbon emission energy expected to increase to 12.5 million tons annually by 2030.

PyroGenesis Canada (PYR), closed Tuesday's trading session at $0.868, up 29.5522%, on 223,259 volume. The average volume for the last 3 months is 19,933 and the stock's 52-week low/high is $0.63/$3.08.

AlTi Global (ALTI)

BullRally, SmarTrend Newsletters, CoolPennyStocks, Greenbackers, HotOTC, Stock Stars, StockEgg, Stockpalooza, HyperGrowthStock, InsiderTrades, MicrocapVoice, Stock Traders Chat, OTCPicks, PennyStockVille, Money Wealth Matters, MadPennyStocks, StockRich, PennyStocks24, OTCReporter, Penny Invest, PennyInvest, SmallCapVoice, Stock Rich, Stratospheric Stocks, StreetAuthority Daily, StreetInsider, The Street, MarketBeat, Wise Penny Stocks, CRWEPicks, Eco Stocks, FeedBlitz, Wealthpire Inc., Wall Street Mover, Wall Street Daily, Investing Futures, Investment House, PennyOmega, Market Wrap Daily, PennyTrader, Stock Guru, Penny Stock Rumble, QualityStocks, PennyTrader Publisher, YourStockReports and The Online Investor reported earlier on AlTi Global (ALTI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

AlTi Global, Inc. (NASDAQ: ALTI) is a financial services firm engaged in the provision of wealth and asset management services to families, individuals, foundations and institutions.

The firm has its headquarters in New York and was incorporated in 2020, on December 18th. Prior to its name change in April 2023, the firm was known as Alvarium Tiedemann Holdings Inc. It operates as part of the asset management industry, under the financial services sector.

The company provides discretionary investment management, non-discretionary investment advisory, trust, and administration services, as well as family office services comprising wealth transfer planning, multi-generational education planning, wealth and asset strategy, trust and fiduciary, chief financial officers and outsourced family office, philanthropy, and lifestyle and special projects services. It also offers corporate advisory, brokerage, and placement agency services to entrepreneurs and firms; and merchant banking services, such as merger and acquisition advisory, corporate broker, private placements, public company and initial public offering advisory, strategic advisory, independent board advice, and structured finance advisory services. This is in addition to providing investment strategy, asset allocation, investment manager selection, risk management, portfolio construction and implementation, and reporting services. Further, the company provides coordination of legal-related and strategic business planning, wealth transfer planning, estate planning, research on trustee placement and multi-generational education planning, administrative, tax planning and concierge, and other services.

The firm, which recently announced its latest financial results, remains focused on expanding its client base globally and its M&A’s, which will drive overall growth.

AlTi Global (ALTI), closed Tuesday's trading session at $4.37, up 1.1574%, on 19,990 volume. The average volume for the last 3 months is 331 and the stock's 52-week low/high is $3.88/$28.49.

Cyrela Brazil Realty SA (CYRBY)

MarketBeat and OTC Markets Group reported earlier on Cyrela Brazil Realty SA (CYRBY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cyrela Brazil Realty SA Empreendimentos e Participações (OTC: CYRBY) (BMV: CYRE3) is a construction firm that is focused on developing, constructing and selling residential properties.

The firm has its headquarters in São Paulo, Brazil and was incorporated in 1962. It operates as part of the residential construction industry, under the consumer cyclical sector. The firm primarily serves consumers in Brazil.

The company is dedicated to being an innovative and sustainable platform with the proposal of offering differentiated solutions for the real estate environment. It operates through numerous subsidiaries in the domestic market, transforming spaces and giving a new soul to cities through combining ethics and aesthetics. The company’s main objective remains leaving a legacy through excellence in delivering sustainable results that contribute to the evolution of society.

The enterprise’s activities are divided into 3 business segments; Real estate, Housing and Services. The real estate division provides homes for high-income families while the housing division offers homes for middle and low-income families. On the other hand, the services division includes land subdivision and rendering of other real estate services. The company develops residential projects independently and through joint venture partnerships.

The firm, which recently announced its latest financial results, remains committed to executing its strategic growth plan to launch unique projects in certain regions which may help to better meet consumer needs. This is in addition to extending the firm’s consumer reach and bringing in additional revenues into the firm.

Cyrela Brazil Realty SA (CYRBY), closed Tuesday's trading session at $3.589, off by 3.5215%, on 331 volume. The average volume for the last 3 months is 100 and the stock's 52-week low/high is $2.19/$3.927.

EcoSynthetix (ECSNF)

We reported earlier on EcoSynthetix (ECSNF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

EcoSynthetix Inc. (OTC: ECSNF) (TSE: ECO) (FRA: 0Y8) is a renewable chemicals firm that is focused on the development and commercialization of bio-based technologies that are used as replacement solutions for synthetic, petrochemical-based adhesives and other related products globally.

The firm has its headquarters in Burlington, Canada and was incorporated in 1996 by Stevem Bloembergen and John van Leeuwen. It operates as part of the specialty chemicals industry, under the basic materials sector. The firm serves consumers around the globe.

The company operates through a single reportable segment and generates revenue primarily from its biopolymer nanosphere technology platform. Geographically, it has a business presence in the Americas, Africa (EMEA) and the Asia Pacific.

The enterprise’s offerings include EcoSphere biolatex, a bio-based latex binder used in paper and paperboard coatings; EcoMer biomonomer for use in pressure sensitive adhesives, ink, toner resins, and paints; and EcoStix, a family of sugar-acrylic and pressure-sensitive adhesives, which include customizable resin grades and formulated grades. It also offers Surflock biopolymers, which are used in paperboard, tissue, and paper applications; and DuraBind engineered biopolymers that enable manufacturers of particle board, MDF, veneers, and laminates to decrease the amount of highly regulated chemicals, such as formaldehyde in their formulation. This is in addition to offering Bioform biopolymers for use in hair gel formulations, serving to hold, style, and protect.

The firm recently released its latest financial results, with its CEO noting that they remained focused on achieving their growth plans. This will, in turn, generate value for its shareholders.

EcoSynthetix (ECSNF), closed Tuesday's trading session at $1.84, even for the day. The average volume for the last 3 months is 24,657 and the stock's 52-week low/high is $1.84/$4.95.

Graphene Manufacturing Group (GMGMF)

We reported earlier on Graphene Manufacturing Group (GMGMF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Graphene Manufacturing Group Ltd (OTC: GMGMF) (CVE: GMG) (FRA: 0GF) is a clean-technology focused firm that is engaged in the manufacture and supply of graphene.

The firm has its headquarters in Richlands, Australia and was incorporated in 2016. It operates as part of the specialty chemicals industry, under the basic materials sector. The firm primarily serves consumers in Australia.

The enterprise provides energy saving and energy storage solutions, enabled by graphene, including those manufactured in-house via a production process. Its segments include the energy savings segment and the energy storage segment. Under the energy savings segment, the firm has focused on Graphene-enhanced heating, ventilating, and air conditioning (HVAC) coatings, lubricants and fluids. Under the energy storage segment, the enterprise is focused on the commercialization of its graphene aluminum-ion batteries in collaboration with the University of Queensland and with funding from the Australian government. The enterprise has also developed a production process to decompose natural gas (methane) into its elements, carbon (as graphene), hydrogen, and some residual hydrocarbon gases. It serves various markets, including transport and earth-moving, facility management, retail, food supply management, education, shopping centers and food outlets, and automotive operations and maintenance, and utilities.

The company recently entered into an agreement with Rio Tinto which will entail accelerating the development and application of its graphene aluminum-ion batteries in the mineral and mining industry. This move will not only bring in additional revenues into the company but also open it up to new growth and investment opportunities.

Graphene Manufacturing Group (GMGMF), closed Tuesday's trading session at $1.6635, up 2.6852%, on 25,857 volume. The average volume for the last 3 months is 620 and the stock's 52-week low/high is $1.0941/$3.35.

Yip's Chemical Holdings (YIPCF)

We reported earlier on Yip's Chemical Holdings (YIPCF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Yip's Chemical Holdings Limited (OTC: YIPCF) (HKG: 0408) is an investment holding firm that is focused on the production and sale of petrochemical products.

The firm has its headquarters in Wanchai, Hong Kong and was incorporated in 1971, on October 25th. Prior to its name change, the firm was known as Hang Cheung Hong. It operates as part of the specialty chemicals industry, under the basic materials sector. The firm primarily serves consumers in the People’s Republic of China.

The company operates through Coatings, Lubricants, Inks and Properties segments. The Coatings segment offers industrial coatings comprising coatings for furniture, and plastic and mechanical products; architectural coatings, including inner and outer wall paints, and water-based emulsion and wood paints for the household paints market; and alkyd, acrylic, UV, amino, and water-based resins. This segment provides its products under the Camel, Aquapro, and VIVA brands. The Lubricants segment provides automotive and industrial lubricants, including engine oils, antifreezes, system coolants, brake oils, lubricating greases, gear oils, automatic gearbox oils, hydraulic oils, among others, under the Hercules brand. It also offers specialty lubricants under the Pacoil brand to the electronics, home appliances, automobiles, bearing manufacturing, engineering machinery, steelworks, port terminals, cement works, toy manufacturing, textiles, and metal processing industries. On the other hand, the Inks segment offers plastic and paper printing inks for use in food, drinks and gift packaging, and paper printing applications, while the Properties segment invests in properties. The company also trades in coatings, solvents, resins, inks, lubricants, and sanitizing products; offers treasury and car maintenance services; and generates and sells electricity.

The firm remains committed to generating value for its shareholders and bolstering its overall growth.

Yip's Chemical Holdings (YIPCF), closed Tuesday's trading session at $0.4838, even for the day. The average volume for the last 3 months is 487,004 and the stock's 52-week low/high is $0.3561/$0.4838.

atai Life Sciences N.V. (ATAI)

QualityStocks, MarketBeat, The Online Investor, StockMarketWatch, StreetInsider, Dynamic Wealth Report, Uncommon Wisdom, Marketbeat.com, MarketClub Analysis, BestOtc, CRWEFinance, CRWEPicks, CRWEWallStreet, DrStockPick, InsiderTrades, PennyOmega, PennyToBuck, Schaeffer's, Small Caps, StockHotTips, TraderPower, Awareness Stocks, StockOodles, Street Insider, The Street, TopPennyStockMovers and ProTrader reported earlier on atai Life Sciences N.V. (ATAI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A recent study has indicated that a nonhallucinogenic form of LSD may be able to treat mood disorders. LSD is one of several psychedelics that have recently gained attention from the scientific community as potential treatments for mental health conditions. Initial psychedelic studies have provided positive results, with researchers finding that hallucinogens such as psilocybin, LSD and MDM can potentially treat a wide variety of psychiatric disorders.

However, psychedelic therapies are marred by the fact that patients have to go through mind-bending psychedelic experiences during treatment, often for hours at a time. This hikes the cost of psychedelic therapy because it often requires the aid of at least two therapists and prevents these professionals from helping more people.

Furthermore, not everyone wants to experience the mind-bending effects of most psychedelics; many just want to take their medicine and go home. As such, scientists have been working to develop psychedelic therapies that don’t have hallucinogenic effects but still deliver mental health benefits.

A nonhallucinogenic analog called 2-Br-LSD could be the medication these patients and scientists have been seeking. Rather than inducing a psychedelic trip, this analog targets and activates the 5-HT2A receptor in the brain instead of the 5-HT2B receptor. This prevents the psychedelic from triggering a psychoactive response and makes it nigh impossible for patients to build up a tolerance to the drug with continued use.

2-Br-LSD also appears to accelerate neuroplasticity, which indicates that it could act as a relatively effective treatment for patients with depression. Animal studies have even found that 2-Br-LSD can help animals cope with stress better, suggesting that it could also be effective as a treatment for chronic stress.

If 2-Br-LSD proves to be safe and effective in human trials, it could open up the field of psychedelic treatments to a vast swathe of the market that isn’t comfortable with being intoxicated by regular psychedelics. Instead of going through several hours of guided psychedelic experiences, patients could simply take a nonhallucinogenic tablet and move on to talk therapy.

It would significantly reduce the cost of psychedelic therapies, making the treatments more accessible to the general public, and also reduce the duration of guided sessions while allowing clinicians to attend to more patients. According to a 2023 study, the LSD analog had a major impact on serotonin receptors and activated the 5-HT2A receptor without triggering hallucinations.

It is less likely to result in tolerance in patients compared to traditional LSD and can ease depression symptoms by boosting neuroplasticity. Although it has exhibited significant potential as a mood disorder treatment, researchers say that more research has to be done to verify the LSD analog’s effects and understand the underlying mechanisms that cause these effects.

While LSD analogs are undergoing scientific scrutiny, plenty of research is also being undertaken on classic psychedelics such as psilocybin by enterprises such as atai Life Sciences N.V. (NASDAQ: ATAI). The future of mental-health care may therefore be dominated by treatments derived from these substances.

atai Life Sciences N.V. (ATAI), closed Tuesday's trading session at $1.79, up 1.1299%, on 487,547 volume. The average volume for the last 3 months is 34.8M and the stock's 52-week low/high is $1.14/$4.96.

Nikola Corporation (NKLA)

Green Car Stocks, Schaeffer's, InvestorPlace, QualityStocks, StocksEarning, MarketClub Analysis, StockEarnings, MarketBeat, The Street, Kiplinger Today, Trades Of The Day, StreetInsider, Daily Trade Alert, The Online Investor, Early Bird, Zacks, Cabot Wealth, Louis Navellier, CNBC Breaking News, Wealth Insider Alert, Investopedia, MarketTamer, GreenCarStocks, Green Energy Stocks, StockMarketWatch, AllPennyStocks, Daily Profit and Outsider Club reported earlier on Nikola Corporation (NKLA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Tesla is now selling its Model 3 and Y EVs in Canada; these are models produced in China. According to a confirmation post on its website, the first electric vehicle shipments from Tesla’s Shanghai manufacturing plant to North America have been completed.

The website displayed Model Y vehicles with rear-wheel drive as well as the long-range, all-wheel-drive Model 3, available to be delivered in British Columbia immediately. The production codes indicated that the vehicles came from Tesla’s Gigafactory in Shanghai.

The two models are eligible for federal subsidies of C$5,000 within Canada, which isn’t the case in the Unites States. America’s subsidies are subject to the country where the EV was made.

As exports from China soar, cost benefits have risen for Tesla and many other automakers. In Canada, a Chinese version of the Model Y was priced at C$61,990. Prior to incentives, the cost of a similar vehicle would have been about 22% higher on the Chinese market.

If Tesla exports from Shanghai to Canada, the company could be able to sell vehicles produced in its Texas and California factories within the United States, which would qualify the vehicles for a possible tax credit of as much as $7,500 through the subsidy program provided for by the Joe Biden administration. Additionally, this creates a fresh market for Gigafactory Shanghai, which was responsible for more than 50% of the total production of the company in 2022.

Tesla’s Gigafactory in Shanghai produces electric automobiles for sale within China and to international markets, such as Europe. However, Tesla is facing increasing price and quality competition from Chinese electric vehicle manufacturers, and its Berlin-based factory has been increasing Model Y production for clients in Europe.

An identifier code is used whenever Tesla lists a vehicle for sale. This code matches the initial three figures on the identification numbers of the vehicle, also known as the VIN. All the VINs on Tesla cars built in Shanghai begin with the letters LURW.

Tesla announced in April that it would launch a new and lower-priced version of its Model Y sports utility vehicle in the Canada market. A rear-wheel drive for this variant would qualify for Canadian government subsidies. The vehicles listed on the company’s website as being eligible for the tax credit have a VIN code as proof that Tesla’s Shanghai facility produced them.

As more manufacturers in China eye export EV markets, the struggle for market share is likely to get tougher for all players across the board, including startups such as Nikola Corporation (NASDAQ: NKLA) that may not have deep pockets as do Tesla and legacy vehicle makers.

Nikola Corporation (NKLA), closed Tuesday's trading session at $0.61, up 3.46%, on 34,892,695 volume. The average volume for the last 3 months is 309,461 and the stock's 52-week low/high is $0.55/$8.97.

Compass Minerals International Inc. (CMP)

SmarTrend Newsletters, MarketBeat, QualityStocks, The Online Investor, Daily Trade Alert, Trades Of The Day, Marketbeat.com, InvestorPlace, Kiplinger Today, The Street, DividendStocks, StreetAuthority Daily, Zacks, StreetInsider, Schaeffer's, All about trends, MarketClub Analysis, The Stock Dork, Insider Wealth Alert, Top Pros' Top Picks, Daily Wealth, Wyatt Investment Research, Daily Market Beat, CRWEFinance, BUYINS.NET, Barchart and MiningNewsWire reported earlier on Compass Minerals International Inc. (CMP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Agriculture completely revolutionized human civilization and allowed humanity to stop their nomadic lifestyles, settle in solitary locations, and build communities. Thanks to agriculture and domestication, humanity had surplus food and could focus its attention on other aspects of the human experience.

The emergence of fertilizers more than a century ago was a significant boon for the agricultural community and allowed people to significantly increase the amount and quality of food they could produce. However, the world is currently in the midst of a fertilizer shortage due to low supply and high costs that have exacerbated fears of an impending food crisis.

Last year, the European Commission stressed the need to reinforce the sustainability and resilience of food systems via a paper dubbed “Ensuring availability and affordability of fertilizers.

With the world population expected to increase by 2 billion people over the next three decades, fortifying our food systems will be even more crucial. Research by Horizon 2020 and Horizon Europe indicates that this could involve reducing reliance on foreign fertilizer imports, reducing nutrient losses and making fertilizers more efficient. This would essentially kill two birds with one stone as it would ensure that food remains affordable for the masses while maintaining soil fertility for future cultivation.

Soil fertility can be maintained by ensuring the soil is full of organic matter and is home to plenty of biodiversity through the use of nutrient-rich side streams, including food waste, sewage sludge or manure to ensure proper recovery of nutrients occurs. The European Commission noted that farmers in Europe can cultivate healthier plants and achieve higher crop yields while limiting their environmental impact and increasing their operations’ resilience to climate change.

Investing in more ecofriendly means of fertilizer production, such as the use of green hydrogen, agroecological plant breeds and crop diversification to reduce the European Union’s reliance on fossil and mineral fertilizers. On top of reducing the EU’s reliance on these types of fertilizers, green hydrogen will significantly reduce emissions from fertilizer use and help push Europe to a greener future.

The European Union (EU) mission — A Soil Deal for Europe — is busy running research to aid in the transition to healthy nutrient-rich soils and sustainable soil management. Additionally, the European Innovation Partnership for Agricultural Sustainability is working to improve innovation, the exchange of knowledge and education to promote farm competitiveness and resilience in the EU.

All in all, the EU currently has 13 projects that are charged with covering a variety of factors that could allow the regional block to make its food system more resilient while reducing emissions from fertilizer use. In the meantime, major fertilizer producers such as Compass Minerals International Inc. (NYSE: CMP) are doing all they can to meet the current demand for these vital agricultural inputs.

Compass Minerals International Inc. (CMP), closed Tuesday's trading session at $32.5, off by 1.6641%, on 317,315 volume. The average volume for the last 3 months is 19.729M and the stock's 52-week low/high is $28.89/$47.68.

The QualityStocks Company Corner

HeartBeam Inc. (NASDAQ: BEAT)

The QualityStocks Daily Newsletter would like to spotlight HeartBeam Inc. (NASDAQ: BEAT) .

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram ("VECG") platform intended for patient use at home, today announced its entry into a strategic alliance agreement ("SAA") with Samsung, extending the existing SAA between LIVMOR and Samsung. HeartBeam acquired LIVMOR assets earlier this year. Under the agreement, HeartBeam and Samsung will identify and define opportunities for collaboration, tapping the HeartBeam team's expertise and patented technology in the assessment and monitoring of cardiac symptoms. "The goal of this partnership is to bring standard of care for cardiac diagnostic capabilities to patients by utilizing cutting-edge technologies of both Samsung and HeartBeam," said Branislav Vajdic, Ph.D., HeartBeam CEO and founder. "Our newly acquired state-of-the-art, FDA cleared, Samsung watch-based arrhythmia detection tool, once integrated with the HeartBeam AIMIGo(TM) telehealth platform, presents a unique opportunity to extend our product capabilities well beyond what is currently available for cardiac patients outside of a medical setting."

To view the full press release, visit https://ibn.fm/rNINu

HeartBeam Inc. (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector 12-lead electrocardiogram (ECG) platform for heart attack detection anytime, anywhere. The company’s proprietary ECG telehealth technology aims to redefine the way high risk cardiovascular patients are diagnosed in ambulatory and acute care settings. HeartBeam’s initial focus is on providing diagnostic data to help physicians with care management of patients with cardiovascular disease.

In August 2022, HeartBeam announced that it submitted its HeartBeam AIMI™ software for approval from the U.S. Food and Drug Administration (FDA). HeartBeam AIMI is a platform technology to improve the speed and accuracy of heart attack detection in acute care settings. The company expects FDA approval by the end of 2022, and a full commercial roll-out of HeartBeam AIMI is targeted for Q1 2023.

HeartBeam sees submission of its first product based on its platform technology as an important milestone toward commercialization, which underscores the company’s continued progress toward making the HeartBeam AIMI platform widely available to help emergency department physicians quickly and accurately identify a heart attack.

While the FDA conducts its regulatory review, HeartBeam will focus on executing key components of its commercialization plan and subscription revenue model. It will also continue to engage in discussions with strategic institutions, including academic centers, regional healthcare systems and regional community hospital systems that can utilize HeartBeam products.

The company is based in Santa Clara, California.

Products

HeartBeam’s development portfolio includes two products:

  • HeartBeam AIMI is software that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack in acute care settings and, as noted above, has been submitted for FDA approval; and
  • HeartBeam AIMIGo™, the first and only credit card-sized 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system for remote heart attack detection.

HeartBeam is developing AIMIGo, a medical-grade detection and monitoring technology for use in remote heart attack detection, thereby allowing physicians to diagnose a patient’s heart attack as it occurs, even if the patient is not at a medical facility. The company’s system, once approved by the FDA, can be used by patients at home or almost anywhere and anytime to help their physicians assess whether chest pain is the result of a heart attack or another cause. While approximately 82% of chest pain ED visits are unnecessary, patients delay approximately 3 to 4 hours after symptoms begin, increasing mortality rates by 40%. The company’s goal is to shorten the time to treatment outside of the medical facility to improve patients’ well-being.

HeartBeam’s AIMIGo is a powerful, portable and easy-to-use prescription-based product. It comprises a smartphone app, a credit card-sized ECG device placed on a patient’s chest, the HeartBeam cloud platform, and a digital portal for the physician to view ECG results and direct patient action. For the first time outside of a medical setting, HeartBeam AIMIGo enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if needed.

Pending FDA clearance, AIMIGo is initially intended to be available by prescription, and is reimbursable under existing remote patient monitoring codes (RPM codes). This provides a new revenue stream to physicians who before did not have a way to monitor these high-risk patients. The RPM codes provide a monthly reoccurring revenue stream to the company, as well. On average, at current reimbursement rates, the practice will receive $1,300+ per year per patient they monitor, and the company will receive $600 per year per patient from this RPM reimbursement.

Market Overview

Adoption rates of telehealth services increased dramatically in recent years, with the COVID-19 pandemic serving as a major driver of growth. Among the areas seeing the greatest expansion are cardiology, radiology, behavioral health and online consultation.

Encouraging this growth, governments are actively developing new policies and reimbursement guidelines to promote the use of digital health platforms. The U.S. Centers for Medicare & Medicaid Services (CMS), for example, has recently expanded reimbursement for telehealth services. U.S. market growth is also being driven by the rising prevalence of chronic conditions and the growing geriatric population.

Remote heart attack detection is a previously unsolved problem with a massive and underserved market that is several times larger than the $2 billion total addressable market (TAM) in the U.S. for ECG cardiac arrhythmia monitoring.

Approximately 8 million Americans have suffered at least one heart attack, and a total of 18 million have been diagnosed with coronary artery disease (CAD). Based on these figures, HeartBeam projects a total addressable U.S. market TAM valued at $10 billion annually for its AIMIGo solution for remote heart attack monitoring of CAD.

Management Team

Branislav Vajdic, Ph.D., Chief Executive Officer and Founder of HeartBeam, Inc, combines over 30 years of experience in technology development and senior management positions. Dr. Vajdic has been deeply involved with the development of HeartBeam’s technology to fit his vision for the company. Prior to HeartBeam, from 2007 to 2010, Dr. Vajdic was CEO and Founder of NewCardio, a publicly traded company in the cardiovascular devices space. From 1984 to 2007, Dr. Vajdic was at Intel, where he held various senior management position. At Intel, Dr. Vajdic was the designer of first Flash memory and two key inventions that enabled Flash as a product and led engineering groups responsible for Pentium 1 through Pentium 4 designs. Dr. Vajdic was awarded two Intel Achievement Awards, the highest level of award for outstanding contributions to Intel. Dr. Vajdic is author of numerous patents and publications in the fields of cardiovascular devices, as well as chip design. Dr. Vajdic holds a Ph.D. in Electrical Engineering from the University of Minnesota.

Jon Hunt, Ph.D., has over 35 years’ experience in the medical/medical device industry with extensive domestic and international experience in general management, clinical/regulatory, sales and marketing. He also has diverse experience in Fortune 500 companies, as well as start-up environments. Dr. Hunt was the Vice President of Clinical Science and Technology, Medical Device Innovation Consortium, from July 2019 to July 2021, and Vice President of Clinical and Regulatory Affairs, Cryterion Medical from January 2018 to June 2019 (acquired by Boston Scientific Corporation in July 2018 for $202M). Dr. Hunt was the Founding President and CEO of Bardy Diagnostics, Inc. from October 2013 to November 2017 (acquired by Hill-Rom Holdings, Inc.). Prior to joining Bardy Diagnostics, Dr. Hunt spent the previous 11 years as the Vice President of Clinical & Regulatory Affairs with Cameron Health, Inc. (acquired by Boston Scientific Corporation). Dr. Hunt spent the previous 10 years with Cardiac Pacemakers, Inc., St. Jude Medical and Cardiac Pathways Corporation. Dr. Hunt began his career with Cardiac Pacemakers, Inc. (now Boston Scientific Corporation) as the Director of Clinical Programs. He subsequently held positions at St. Jude Medical in Clinical Affairs and as the Business Unit Director for the Cardiac Rhythm Management division for Europe, the Middle East and Africa. At Cardiac Pathways Corporation, Dr. Hunt held various executive positions as Vice President of International Sales and Marketing and Vice President of Worldwide Sales and Marketing (acquired by Boston Scientific Corporation). Dr. Hunt received his Ph.D. in Motor Control from The Pennsylvania State University, his Master’s from California State University, Long Beach and his undergraduate degree from Keele University in the United Kingdom.

Rick Brounstein, HeartBeam’s Chief Financial Officer, combines over 30 years of experience in health technology senior management. Since 2017, Mr. Brounstein has been and is currently a partner of Hardesty, LLC, a financial services firm, and Mr. Brounstein is currently a managing director of CTRLCFO, LLC, a firm Mr. Brounstein founded in 2016 to support funded start-ups in life science and technology. From 2008 to 2011, Mr. Brounstein was Chief Financial Officer of NewCardio, Inc., a microcap public company in the cardiology space, and, over his career, he has been with nine other companies in life science or technology, holding positions including Chief Financial Officer, Chief Operating Officer, Treasurer and Accounting Manager. From June 2001 through November 2007, Mr. Brounstein held several positions at Calypte Biomedical Corporation, a publicly traded medical device company, including Chief Financial Officer and Executive Vice President. In January 2007, Mr. Brounstein was appointed as the National Member Representative for the 2007 COSO Monitoring Project, which published new guidelines for monitoring internal financial controls in February 2009; Mr. Brounstein subsequently was a member of the FEI task force that issued the updated COSO Internal Control Framework in 2013. In March 2005, Mr. Brounstein was appointed to the SEC Advisory Committee on Smaller Public Companies. Mr. Brounstein earned his Certified Public Accountant (CPA) certification while working at Arthur Andersen LLP, formerly a public accounting firm. Mr. Brounstein holds a B.A. in accounting and an M.B.A. in finance, both from Michigan State University.

Ken Persen, HeartBeam’s Chief Technology Officer, combines over 28 years of experience in the medical device and digital health industries in engineering and senior management positions. Mr. Persen has been involved in several companies in Cardiac Rhythm Management, holding positions including Chief Executive Officer, Chief Technology Officer, Executive Vice President and Director of Engineering. Since 2016 and prior to joining HeartBeam, Mr. Persen was the Chief Technology Officer at LIVMOR, Inc., a digital health company. In addition, from 2016 through November 2021, he was also Chief Executive Officer of LIVMOR. Prior roles included Director of Engineering at Cameron Health (acquired by Boston Scientific), a late-stage medical device start up, and engineering and management positions at Guidant Corp. (acquired by Boston Scientific), a large medical device manufacturer. He has an undergraduate degree from University of Minnesota, Duluth, with a BA in Computer Science.

HeartBeam Inc. (NASDAQ: BEAT), closed Tuesday's trading session at $2.36, up 8.2569%, on 19,763,738 volume. The average volume for the last 3 months is 6,518 and the stock's 52-week low/high is $1.12/$6.74.

Recent News

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

The QualityStocks Daily Newsletter would like to spotlight BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV).

Analysts at Aegis Capital Corp. continue to recommend shares of the company with a Buy rating and a $70 target price

Data from pre-clinical trial indicate that BiondVax's NanoAb may effectively serve as both a therapeutic and protective prophylactic drug, further enhancing its value proposition

BVXV reiterated further NanoAb development beginning with NanoAbs targeting immune system cytokines such as IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis

BiondVax aims to optimize the use of assets and generate additional revenues by offering its drug development services and cGMP manufacturing capabilities to others

BiondVax Pharmaceuticals (NASDAQ: BVXV), an innovative biotechnology company developing unique NanoAb immunotherapeutic products for the treatment of infectious disease and large market autoimmune disorders, recently published the financial results for the three months ended March 31, 2023 – Q1 2023 – and provided a business update (https://ibn.fm/GBZmz).

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, BiondVax signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. BiondVax anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of BiondVax’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

BiondVax has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, BiondVax will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. BiondVax anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future BiondVax drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is BiondVax’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Chief Engineer and Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at BiondVax. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at BiondVax. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining BiondVax, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at BiondVax. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to BiondVax through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), closed Tuesday's trading session at $1.86, up 2.1978%, on 6,524 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $6.74/$.

Recent News

FingerMotion Inc. (NASDAQ: FNGR)

The QualityStocks Daily Newsletter would like to spotlight FingerMotion Inc. (NASDAQ: FNGR) .

FingerMotion, Inc. (NASDAQ: FNGR) (the " Company " or " FingerMotion "), a Big Data company with revenue streams from mobile recharge, SMS, and Insuretec services, is pleased to report its financial results for the year ended February 28, 2023. To review the full financial results, please view the Company's recent 10-K filing at www.sec.gov/edgar/search , which should be read in connection with this news release.

FY 2023 Financial Summary (results expressed in US$ unless otherwise indicated):

Reported annual revenue of $34.05 million which was an increase of $11.12 million or 49% compared to FY 2022 (includes SMS & MMS, Telecommunications Products & Services businesses, and Big Data);

Reported Year over Year annual growth in Telecommunications Products & Services business revenue of $18.35 million or 212% compared to FY 2022;

Reported Year over Year annual decline in SMS & MMS business revenue of $7.53 million or 53% compared to FY 2022;

Reported Year over Year annual growth in Big Data revenue of $0.31 million or 233% compared to FY 2022;

Reported gross profits of $2.32 million which was a decrease of $0.5 million or 17.6% compared to FY 2022;

Reported annual cost of revenue of $31.74 million which was an increase of $11.62 million or 58% compared to FY 2022;

Reported operating expenses of $8.98 million which was an increase of $1.30 million or 17% compared to FY 2022;

Reported annual net loss of $7.54 million which was an increase of $2.60 million or 53% compared to FY 2022;

Basic and Diluted loss per share of $0.17;

At February 28, 2023, FingerMotion had $9.24 million in cash, a working capital surplus of $15.23 million and a positive shareholders' equity of $12.97 million;

At February 28, 2023, total assets were $17.55 million, total current liabilities were $2.04 million and total liabilities were $4.57 million; and

49,432,214 common shares were issued and outstanding as of February 28, 2023.

FingerMotion Inc. (NASDAQ: FNGR) is an evolving technological company with core competencies in mobile payment and recharge platform solutions in China. FingerMotion is in the process of developing additional value-added technologies to market to users.

Founded in 2016, FingerMotion’s goal is to serve over a billion users in the Chinese market and expand its model to other regional markets. The company has offices in Hong Kong, Shanghai and New York City.

Current Offerings

FingerMotion is analyzing and transforming mobile data to improve the lifestyle of the public through technology and innovation. The company’s current offerings include:

  • Telecommunications Products and Services – FingerMotion’s proprietary universal exchange platform, ‘PigeonHole Integration System (PIS)’, offers seamless integration between telecom operators and online stores. The service platform’s offerings include top up and recharge, data plan, mobile phone, loyalty points redemption and subscription plans. The platform offers reliable and secure transactions, real-time reconciliation, simple integration for partners and efficient settlements.
  • SMS and MMS Services – The integrated platform is registered as FingerMotion’s IP in China and provides a robust back-end control panel for corporate partners to manage their own messaging settings. FingerMotion’s clients range from insurance to financial industries, ecommerce firms, airlines and more. The platform offers competitive pricing for partners and provides quick and efficient review to meet timely marketing initiatives.
  • Big Data Insights – FingerMotion brings Big Data-enabled insurance solutions through its Big Data Insights arm, Sapientus. The company’s strategic partnerships with the largest Chinese telecommunications giants allow access to uncover behavior insights through geolocation and mobile data usage. Its Big Data offerings include risk scoring, precise marketing, simplified underwriting and customized products.
  • Rich Communication Services (RCS) – FingerMotion’s RCS platform will be a proprietary business messaging solution that enables businesses and brands to communicate their services to customers via 5G infrastructure. The company expects its RCS platform to offer a better user experience, more efficiency and cost-effectiveness when compared to other solutions.

Telecommunications and Insurtech Markets

The global telecommunications market was valued at $1.74 trillion in 2019 and is expected to grow at a CAGR of 5% from 2020 to 2027. The steady increase is expected to be driven by the adoption of 5G and the increased popularity of Internet of Things (IoT) applications.

The Chinese telecom market was valued at $254.1 billion in 2017 and is also constantly expanding. The current Chinese telecom market is dominated by three mobile operators – China Mobile, China Unicom and China Telecom, which together are responsible for around 1.6 billion active subscribers (https://ibn.fm/zfwy9).

In addition, the insurtech (insurance technology) market was valued at $2.72 billion globally in 2020 and is expected to grow at a CAGR of 48.8% from 2021 to 2028. The large increase is attributed to the rising use of technology solutions for everyday activities like acquiring insurance coverage (https://ibn.fm/TGo7D).

Through its proprietary platforms and technologies, FingerMotion is uniquely positioned to capitalize on the telecom and insurtech markets’ growth and opportunities.

Management Team

Martin J. Shen is the Chief Executive Officer of FingerMotion Inc. He has over 15 years of experience in senior management roles within entrepreneurial startups and large multinational corporations. He has acquired a wide range of corporate management, financial oversight and operation administration expertise through these roles. In his most recent role, he founded Imperial Distributors (formerly known as AP Martin Pharmaceutical Supplies Ltd.), establishing the company as the preferred choice for distributional support to regional pharmacies throughout Western Canada. Before founding Imperial, Mr. Shen served as the Chief Operating Officer and Chief Financial Officer at Wales and Son Industrial (formerly Weir Minerals), a firm specializing in global delivery and support for mining slurry equipment. He began his career at PricewaterhouseCoopers in Vancouver, with work tours in the tax department in Singapore and the tax audit and advisory group in Hong Kong. Mr. Shen is a U.S. Certified Public Accountant and holds a Bachelor of Science from the University of British Columbia.

Lee Yew Hon is the company’s Chief Financial Officer. From 2006 until November 2020, he was the Chief Financial Officer of Cubinet Interactive Group of Companies, and he also took on the Chief Operating Officer role in 2011. During his tenure, he was instrumental in leading Cubinet and building teams across the Southeast Asia region, setting up financial processes within a short time. Mr. Lee spearheaded the growth of Cubinet to other regions, including Europe, the Middle East and Russia. He received his diploma from Tunku Abdul Rahman College in 1996. He is a Chartered Accountant, a member of the Malaysia Institute of Accountants (MIA) and an Associate Member of the Chartered Institute of Management Accountants, UK (ACMA).

Li Li is the Senior Vice President of FingerMotion. She recently served as Advisor to Shenzhen WuYiKa Technology Co. Ltd., a comprehensive service platform dedicated to online service distribution and payment. The company has become a fast and efficient provider of new media marketing solutions for the mobile internet. She has held high-level management positions with multiple industry names, including Hangzhou JiuYue Information Technology Co. Ltd. and Hangzhou LingXuan Information Technology. Ms. Li started her career in 2004, founding Shanghai ChuangYeZZ Network Technology Co. Ltd. and serving as its Vice President. With the close cooperation of local operators, the company launched SMS, MMS, WAP, mobile JAVA games, Hunan Satellite TV e-magazine and other wireless internet services to meet the rapid development of wireless internet and application requirements. She received her degree from Nanjing Academy of Engineering.

FingerMotion Inc. (FNGR), closed Tuesday's trading session at $1.72, up 13.9073%, on 196,774 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.62/$9.795.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

While delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD) are the most publicly known cannabinoids, cannabis produces more than 100 different cannabinoids. Delta-9 THC is the main psychoactive agent in cannabis, and it is illegal at the federal level and in states that do not allow recreational or medical cannabis sales.

In recent years, players in the cannabis industry have turned to another psychoactive cannabinoid called delta-8 THC. The result has been an influx of delta-8 THC products even though the FDA has not evaluated or approved such products as safe for public consumption. The labeling on these products often contains misleading claims, the FDA says, and the products are often marketed for medical or therapeutic uses that aren't approved by the appropriate authorities.

Delta-8 THC products have become incredibly popular in states without recreational cannabis markets because they allow users to experience psychoactive effects without buying black-market cannabis. Cannabidiol (CBD) has also enjoyed significant growth in recent years based on claims of its medical potential, achieving a net worth of $5 billion only a few years after the 2018 Farm Bill legalized the cultivation and sale of industrial hemp and its derivatives. As the DEA moves to only allow natural cannabinoids to be commercialized in the states where marijuana is legal, more opportunities may become available for cannabis companies and related companies such as Advanced Container Technologies Inc. (OTC: ACTX) may do more brisk business as a result. This is because only legally permitted products adhering to the established regulations will be allowed on the market, thereby giving cannabis growers a better chance of succeeding.

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.

Products

Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.

Containers

ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Tuesday's trading session at $0.285, up 10.9813%, on 202 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.032/$1.00.

Recent News

Starco Brands Inc. (OTCQB: STCB)

The QualityStocks Daily Newsletter would like to spotlight Starco Brands Inc. (OTCQB: STCB).

Starco Brands reported revenue of $7.8 million for the year ended December 31, 2022 – a YoY increase of 1,060%

Starco Brands had revenues of $11.1 million Q1 of 2023, increasing 1,107% over the prior year period

Leveraging an aggressive M&A strategy to disrupt the CPG industry, Starco Brands sparks excitement in the everyday

Starco has completed the acquisition of three vertical-defining brands since Q3 2022, putting it on a run rate of roughly $67M in annual revenue

Starco Brands (OTCQB: STCB) is a modern-day invention factory holding fast to its unwavering mission to invent and acquire consumer products and brands with behavior-changing technologies that spark excitement in the everyday. Since 2022, the company has adopted an aggressive M&A strategy to fuel its expansion and disrupt the CPG industry.

Starco Brands Inc. (OTCQB: STCB) is a modern-day invention factory. The company’s unwavering mission is to invent and acquire consumer products and brands with behavior-changing technologies that spark excitement in the everyday.

This consumer product company has grown from a few million dollars in revenue to a current run rate of approximately $67 million in annual revenue in one year.

The company has succeeded by identifying whitespaces in eight core consumer categories and then either: 1) leveraging its internal R&D capabilities and dedicated manufacturing network to invent new technologies and brands or 2) utilizing the management team’s extensive M&A experience to acquire brands that fill the industry void, delighting consumers and retailers alike.

Whether the brand is developed internally or acquired, the company employs a modern marketing playbook to ensure its brands are at the forefront of culture; garnering unprecedented media attention and engagement that supports a robust sales network.

Starco Brands’ core competencies are inventing technologies, acquiring companies, marketing, building trends, pushing awareness, penetrating media (social and otherwise) and executing cutting edge pull-through strategies with a roster of globally recognized celebrities, influencers and media and distribution partners.

A commitment to changing the way people approach everyday activities is innate in the company’s corporate DNA.

The company is based in Santa Monica, California.

Brands

Whereas other consumer products companies are content with evolution, Starco Brands has its mind set on creating a revolution across the industry. From disrupting the spirits industry with Whipshots, the world’s only vodka-infused whipped cream, to Soylent, the original food tech company, Starco Brands is putting the CPG world on notice. Its portfolio of brands includes:

  • Whipshots is a first-of-its-kind alcoholic whipped cream launched in 2021 with celebrity partner Cardi B. Consumers have embraced this boozy concoction, putting it on top of cocktails, coffees and desserts, or enjoying it straight from the can. In just over a year, the brand has sold over 2 MILLION cans, making it one of the fastest growing spirits in history.
  • Winona Pure gives consumers movie theatre popcorn in the comfort of their own homes. All the flavor and none of the additives is the story behind these all-natural, non-GMO popcorn seasoning sprays. A simple spray is all it takes to add the perfect pop of flavor to the classic theatre treat.
  • Art of Sport, co-founded by the great Kobe Bryant, is the number one body care brand for athletes. With a growing line of personal care products tested by the world’s greatest athletes, these daily skin essentials give consumers everything they need to feel fresh, stay protected and confident and perform at their peak every day.
  • Skylar is the first and only line of perfumes on the market that are hypoallergenic and safe for sensitive skin. With the strong support of industry titan Sephora, the brand has quickly attracted a loyal following.
  • Soylent is a technological feat. Originally funded by Google Ventures and Andreessen Horwitz, Soylent is dubbed as the world’s most perfect food. Made from sustainably grown plant-based ingredients, Soylent’s line of products is scientifically developed to provide all the functional ingredients, vitamins, minerals, fats, carbohydrates and protein that the body needs – all in convenient, delicious and affordable packages. Soylent’s innovative product line-up includes complete nutrition powders, ready-to-drink shakes, 100-calorie snack bars, high protein nutrition shakes and energy boosting nutrition shakes. Soylent was also the recipient of the 2023 Product of the Year Award by Kantar, a global leader in consumer research.

With award-winning marketing talent, Starco Brands develops robust, integrated marketing plans for every brand in its portfolio, ensuring an impactful presence across all verticals.

Market Outlook

Starco Brands’ varied brand portfolio gives it access to the growth of numerous product categories that are ripe for innovation.

Through its February 2023 acquisition of complete nutrition pioneer Soylent, Starco Brands is positioned to capitalize on the projected growth of the plant-based nutrition space. Research firm Statista valued the plant-based nutrition market at $29.4 billion in 2020 and forecasts its value at nearly $162 billion by 2030, representing a CAGR of 18.7% for the period.

Likewise, Starco Brands gained improved access to the global fragrance market through its December 2022 acquisition of Skylar. According to a report by Grand View Research, the global perfume market was valued at $50.85 billion in 2022 and is expected to grow to a value of nearly $80 billion by 2030, achieving a CAGR of 5.9% over the forecast period.

The company is primed to expand its access to other growth verticals as it advances on its path to invent and acquire behavior-changing technologies and brands.

Management Team

Ross Sklar is the CEO of Starco Brands. A chemical formulator by trade, he started his first company while still in college. Since 2004, he has made over a dozen acquisitions with multiple exits and controls an eclectic collection of industrial, household, personal care and food and beverage manufacturers covering many consumer-packaged goods categories.

Darin Brown is the Chief Operating Officer of Starco Brands. With over 20 years of experience in chemical manufacturing, business development, finance and mergers and acquisitions, he has scaled the company from the ground up. He oversees all internal operations for Starco Brands and is an integral liaison between the company and Mr. Sklar’s manufacturing facilities.

David Dreyer is Chief Marketing Officer of Starco Brands. With over 25 years of experience working with blue chip and startup brands, he oversees all marketing initiatives for the company. Mr. Dreyer comes to Starco having worked with such standout brands as Apple, Pepsi, Pizza Hut, Dr Pepper, Snapple, Infiniti, The GRAMMY’s, Honda and Stamps.com. He is also a Professor of Advertising at USC’s Annenberg School for Communication.

Starco Brands Inc. (STCB), closed Tuesday's trading session at $0.121, even for the day, on 1 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0725/$0.265.

Recent News

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

Energy Fuels (NYSE American: UUUU) (TSX: EFR), a leading U.S.-based critical minerals company, has released the results of elections held during its annual meeting of shareholders. The virtual meeting was held on May 25, 2023. An item on the agenda was the election of directors, and Energy Fuels reports that all 10 nominees who were proposed for management were elected by shareholders. Votes were cast by a combination of proxy and electronic poll. The 10 directs that were elected include the following: J. Birks Bovaird, Mark S. Chalmers, Benjamin Eshleman III, Ivy V. Estabrooke, Barbara A. Filas, Bruce D. Hansen, Jaqueline Herrera, Dennis L. Higgs, Robert W. Kirkwood and Alexander G. Morrison.

To view the full press release, visit https://ibn.fm/omdZg

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR),based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

  • White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
  • Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
  • Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon‐free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

  • Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
  • Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
  • Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

  • La Sal Complex (Utah)
  • Whirlwind Mine (Colorado/Utah)
  • Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

Energy Fuels Inc. (UUUU), closed Tuesday's trading session at $5.71, off by 3.2203%, on 1,229,069 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $4.69/$8.245.

Recent News

NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW)

The QualityStocks Daily Newsletter would like to spotlight NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW).

Amazon Prime members in the United States will soon be able to buy a variety of generic medications and enjoy doorstep delivery in exchange for a $5 monthly fee. The e-commerce giant recently announced the launch of a new program called RxPass that would grant U.S. Prime members access to more than 50 medications.

Speaking to Reuters, Vin Gupta, Amazon Pharmacy chief medical officer, said that the medication provided by the platform can be used to treat more than 80 chronic conditions. These include diabetes, male pattern baldness, anxiety and high blood pressure — conditions that tend to affect a lot of Americans.

The announcement marks Amazon's most recent foray into the healthcare industry. It began in 2018 when the online retailer acquired the online pharmacy PillPack and began setting up a pharmaceutical price comparison site and a prescription-delivery service. In November 2022, Amazon announced that it was launching a telehealth platform called Amazon Clinic that would connect healthcare providers with patients suffering from more than 20 common conditions. The platform wouldn't take insurance from customers and would operate on a cash-only basis. With Amazon welcoming partnerships with a variety of healthcare ecommerce platform providers such as NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW), the way people access different services related to healthcare could be set for a major transformation over the coming years.

NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW), a next generation e-commerce platform, was created with vision and purpose to capitalize on high growth sectors and global markets. The company collaborates with businesses – large and small – to simplify and accelerate online commerce and uniquely enables customers and partners to optimize their e-commerce reach, presence and revenue. NextPlat recently launched a new e-commerce development program to provide American businesses with easy access to the massive Chinese consumer market.

Current Initiatives

NextPlat provides cutting edge technology in an advanced e-commerce ecosystem. The company is actively expanding its global network of online storefronts serving thousands of consumers, enterprises and governments. The company also has developed a next generation platform built for Web3 that enables the creation and sale of digital assets, as well as optimizing e-commerce transactions and business building activities. The company’s current initiatives include:

  • E-Commerce Development Program – In April 2023, NextPlat announced it had entered into a merchant sourcing agreement with Alibaba.com Singapore E-Commerce Private Limited (“Alibaba”) and its Tmall Global e-commerce platform whereby the two companies will collaborate to increase the sale of products produced and sold by American companies to the multi-trillion-dollar Chinese consumer market. Alibaba’s Tmall Global e-commerce platform will provide NextPlat customers a turn-key solution through which products can be sold to the Chinese consumer market. The launch of the Florida E-Commerce Development Program is the first in a series of new NextPlat programs designed to assist U.S. businesses in expanding their online sales capabilities to reach new international customers in the Chinese market. NextPlat intends to rapidly expand this unique e-commerce development opportunity to businesses throughout the United States and all of North America, as well as Central and South America. The new development program features NextPlat’s turnkey global e-commerce solution for customers and leverages NextPlat’s relationships with key partners, including Tmall Global, China’s largest cross-border B2C online marketplace.
  • Progressive Care Inc. – In August 2022, NextPlat completed a strategic $7 million investment in Progressive Care Inc. (OTCQB: RXMD), a personalized health care services and technology company. In a news release announcing the investment, NextPlat CEO Charles M. Fernandez noted that the company is “committed to harnessing the power of digital technologies to capitalize on the ongoing digital transformation of Progressive Care and the entire health care industry.” NextPlat intends to accelerate Progressive Care’s digital health care transformation with the launch of a new e-commerce platform for health care products later this year.
  • NextPlat NFT Platform – Building on its existing e-commerce initiatives, NextPlat is working to bridge the gap between tangible and digital e-commerce marketplaces by incorporating burgeoning Web3 technologies. The company intends to launch a fully integrated NFT platform in the coming months that will enable brands to create, manage and authenticate digital assets while serving as a new source of revenue for NextPlat. Through this model, the company will receive a portion of the revenue generated from branded NFT drops, as well as subsequent secondary market transactions.
  • Global Telesat Communications and Orbital SatCom Corp. – Targeting both domestic and international markets, NextPlat’s subsidiaries leverage partnerships with major e-commerce platforms such as Amazon, Alibaba, eBay and Walmart to serve a growing base that includes more than 50,000 corporate, governmental and individual customers. In total, the brands market more than 10,000 individual products, with a focus on satellite-based connectivity solutions. In addition to exploring accretive M&A opportunities, NextPlat aims to diversify its range of products and broaden its geographic footprint moving forward in an effort to better capitalize on the tremendous growth potential in the United States, Europe and Asia.

“Our goal for 2023 and beyond is to leverage our improved operational capabilities and enhanced leadership team as we expand our offerings in communications and connectivity into the high-growth health care market where we intend to launch an array of innovative new offerings,” Fernandez said in a March 2023 news release detailing the company’s record top-line performance. “Although there remain supply chain headwinds and the challenge of global inflation, we are confident that we have the right combination of market-tested expertise, technology and partnerships that will enable us to bring the power of e-commerce to more customers, brands and industries in the United States and abroad.”

Market Opportunity

The rapid growth of e-commerce over the last decade is expected to continue for the foreseeable future. According to data published by Forbes, roughly 20.8% of all retail purchases are expected to take place online in 2023, accounting for total sales of $6.31 trillion worldwide. It total, e-commerce sales are expected to grow by 10.4% YoY in 2023, accounting for a whopping 24% of all retail purchases by 2026.

For NextPlat, existing partnerships in the industry could be key to capitalizing on this growth. The Forbes report indicates that Amazon accounts for roughly 38.7% of e-commerce sales, while sites like Walmart, eBay and Alibaba round out the list of most visited e-commerce websites. Alibaba is especially interesting due to NextPlat’s recent strategic merchant sourcing agreement with Tmall Global. The Chinese market is “mammoth,” as a recent Alizila report noted. The country’s annual online retail sales of physical goods have nearly doubled in the last five years, reaching approximately 13.8 trillion yuan in 2022, which is nearly $2 trillion USD.

The health care portion of the e-commerce market is generating particularly bullish forecasts, bolstered by the continued adoption of the 340B Drug Pricing Program in the U.S., which requires most drug manufacturers to provide outpatient drugs to covered entities at significantly reduced prices. Industry reports suggest that the global health care e-commerce market will expand at a compound annual growth rate of 16.8% from 2022 to 2030, climbing to a value of more than $1.37 trillion by the end of the forecast period.

Management Team

Charles M. Fernandez, CEO, Executive Chairman and Director of NextPlat, has over three decades of experience in identifying profitable start-up and dislocation opportunities, building significant value and executing exit strategies as an entrepreneur and global investor. Successful across multiple sectors, Fortune Magazine actually labeled Fernandez ‘a restructuring whiz’. As President of Fairholme Capital Management, which he joined in 2008, Mr. Fernandez co-managed all three Fairholme funds and brought in a $2 billion gain for shareholders. Throughout his impressive career, he has participated in more than 100 significant mergers, acquisitions and product development projects across multiple industries. Mr. Fernandez was the founder, Chairman and CEO of eApeiron Solutions LLC, a brand protection and e-commerce company in partnership with Alibaba (NYSE: BABA) and Eastman Kodak (NYSE: KODK), which was successfully sold to Smartrac, a unit of Avery Dennison Corp. (NYSE: AVY).

Rodney Barreto is Chairman and CEO of the Barreto Group and Director of Nextplat. Mr. Barreto’s business career spans over 35 years, including his role at the Barreto Group and, earlier, as the founding partner of Floridian Partners LLC, a corporate and public affairs consulting firm recognized by policy makers as one of the top in its industry in Florida. He chaired the Super Bowl Host Committee in 2007, 2010 and 2020, helping to raise more than $100 million for the success of Miami Super Bowls. As a philanthropist and conservationist, Mr. Barreto is also a three-time appointee to the Florida Fish and Wildlife Conservation Commission, where he has served for over 10 years including holding the title of Chairman eight times. He has twice chaired the Annual U.S. Conference of Mayors, was Chairman of the 1999 Breeder’s Cup Championship held in South Florida and was the Chairman of the 1999 Sister Cities International Convention in Miami. Currently, Mr. Barreto is the Membership Chairman of the Florida Council of 100, and a member of the Boards of Fairchild Tropical Botanic Garden, the Baptist Health South Florida Giving Society, the Bonefish and Tarpon Trust, the Guy Harvey Ocean Foundation, and a member of Miami Dade County Schools Superintendent Carvalho’s Business Advisory Council. Prior to his career in public affairs and real estate, Mr. Barreto was a City of Miami police officer and is a member of the Florida Highway Patrol Advisory Council.

NextPlat Corp. (NXPL), closed Tuesday's trading session at $2.15, off by 1.3761%, on 34,945 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.2115/$4.26.

Recent News

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is reporting results from the phase 1 portion of its Acclaim-1 phase 1/2 clinical trial. The trial is designed to evaluate Genprex's proprietary REQORSA(R), used in combination with Tagrisso(R) (osimertinib) for the treatment of late-stage non-small cell lung cancer ("NSCLC"). According to the report, results show that REQORSA was generally well tolerated with no dose-limiting toxicities. Based on the report, the Safety Review Committee ("SRC") has determined that the recommended phase 2 dose of REQORSA will be 0.12 mg/kg, which was the highest dose level delivered in the phase 1 portion of the trial and is twice the highest dose level delivered in a previous trial; the SRC also recommended the trial advance to phase 2. The company anticipates that phase 2 will begin in Q3 2023. "We are proud of the notable progress we made during the phase 1 portion of the Acclaim-1 clinical trial, and the SRC recommendation to move into the phase 2 expansion portion of the trial is another validation for our REQORSA development program," said Genprex president and chair Rodney Varner in the press release. "As we move into the phase 2 expansion portion of the trial, we remain steadfast in our efforts to bring new therapies to lung cancer patients with unmet medical need."

To view the full press release, visit https://ibn.fm/n5R3v

Genprex Inc. (GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (NASDAQ: GNPX), closed Tuesday's trading session at $0.8032, off by 9.7528%, on 719,363 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.7225/$2.67.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

The market for EVs has grown rapidly in recent years and is expected to continue growing at a fast pace over the coming decade

MULN's two manufacturing facilities are gearing up for increased production volume

The company is meeting noteworthy milestones with each of its EV brands

As the EV market steadily rises in the coming years, Mullen Automotive (NASDAQ: MULN) is positioning itself to be a strong player in the space. The Southern California–based automotive company recently released a corporate update outlining the impressive growth it has seen in the past few months (https://ibn.fm/nhIqM).

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Tuesday's trading session at $0.7592, off by 6.0512%, on 77,086,056 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.72/$42.75.

Recent News

IGC Pharma Inc. (NYSE American: IGC)

The QualityStocks Daily Newsletter would like to spotlight IGC Pharma Inc. (NYSE American: IGC).

A study by testing company and medical lab Quest Diagnostics has revealed that Americans are failing marijuana tests in unprecedented numbers. The firm's annual analysis found that the number of U.S. employees who tested positive for marijuana was the highest Quest Diagnostics had seen since it started collecting data on workplace drug testing in 1988.

After analyzing more than 6 million urine tests for traces of marijuana in 2022, the firm found that 4.3% were positive for cannabis compared to 3.9% in 2021. Quest Diagnostics tested urine samples from general employees. This group excludes safety-sensitive and federally mandated employees, such as truck drivers and pilots who go through regular drug testing.

Now that dozens of states have medical and recreational cannabis markets, millions of Americans have access to legal, regulated cannabis. However, since federal law still considers cannabis an illegal drug, cannabis users often find themselves facing legal repercussions for using cannabis in accordance with their state laws. Given that more than 30 states across the country permit the medical use of marijuana, it isn't surprising that entities such as IGC Pharma Inc. (NYSE American: IGC) are taking this medical use a step further by developing formulations that can be approved by the FDA for use within the healthcare system.

IGC Pharma Inc. (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (THC) compound plus another molecule (www.clinicaltrials.gov). As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC-based formulation on Alzheimer’s patients.

The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines. Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

Neuro Psychiatric Symptoms (NPS) are not only debilitating for Alzheimer’s patients; they also place an immense emotional burden on their caregivers. Beyond reducing symptoms, IGC-AD1’s active molecules and TGR-63 have also shown promise in preclinical trials to reduce important hallmarks of Alzheimer’s including plaques and tangles, as well as improving the treatment of memory loss.

Over the past eight years, the IGC team has amassed a deep knowledge of cannabinoid science, including extraction, isolation, purification, and development. The company’s strategy is to leverage its unique end-to-end capabilities, platform, and expertise to develop a class-leading program and bring it to market quickly and cost efficiently to treat neurodegenerative diseases such as Alzheimer’s.

The company also has a family of cannabidiol (CBD)-based consumer products (www.Holief.com) such as pain relief creams, pain relief gels, purpose gummies, tinctures, and capsules targeting women’s wellness, with a particular focus on premenstrual syndrome (PMS) and dysmenorrhea (period cramps). In addition, the company targets individuals that need sleep-aids with its specially formulated low melatonin cannabinoid gummies.

IGC has also introduced a low-calorie CBD- and caffeine-infused energy beverage brand (www.SundaySeltzer.com) that is currently available for purchase. The company’s brands are founded on the belief that effective natural solutions should be affordable and accessible to everyone. As the demand for natural products targeting women’s wellness and energy drinks continue to grow, these products are seeing strong traction in the market.

The company operates three facilities – a large GMP (Good Manufacturing Production Standards) certified facility that includes extraction, distillation, and manufacturing, in Washington State; a GMP-211 (pharmaceutical) grade facility in Maryland; and a facility licensed for controlled substances including cannabis in Bogota, Colombia, with complete access to legal licensed cannabis where the company conducts its testing.

In addition, the company’s development under Magistral Formulations is approved by INVIMA (Colombia National Food and Drug Surveillance Institute) to treat neurological disorders, non-oncological chronic pain, and mental disorders.

IGC’s intellectual property (IP) portfolio comprises of eight patents that it controls and seven patent applications. The portfolio includes #11,446,276, a patent for extreme low dose THC treatment of Alzheimer’s that was granted in September 2022.

The company is headquartered in Potomac, Maryland.

IGC-AD1

IGC-AD1 is the company’s leading drug candidate for the treatment and relief of Alzheimer’s symptoms. A significant amount of research on Alzheimer’s cell lines has shown that the active agents in IGC-AD1 reduce plaques and neurofibrillary tangles that are the hallmarks of Alzheimer’s. Further, micro-dosing of THC, as shown in cell lines, could increase the functioning of mitochondria and potentially promote the growth of new neural pathways (neurogenesis). The research shows that micro-dosing of THC affects the brain radically differently from the normal higher dosing of THC.

While there is a significant body of research showing that THC is neuro-toxic at normal levels of dosing, micro-dosing of THC has been shown to be non-toxic to neurons. With the results of these preclinical studies, the company developed an oral formulation, IGC-AD1. The company recently completed a safety and tolerability Phase 1 trial on Alzheimer’s patients and has initiated a Phase 2, multi-site, double-blind, randomized, placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease at sites in the U.S. and Canada. IGC expects the Phase 2 trial to take between 9 and 12 months to complete, barring unknown factors such as, for example, a resurgence of COVID and the enforcement of lockdowns and travel restrictions.

With further successful trials and FDA approvals, IGC hopes to bring a drug based on natural THC as an effective treatment for agitation in Alzheimer’s to market.

TGR-63

The company’s other molecule, TGR-63, has been shown to reduce the neurotoxicity that impacts memory loss in preclinical trials with mice. On a dose dependent manner, transgenic Alzheimer’s mice treated with TGR-63 showed improvement in memory relative to control.

Both drug candidates, IGC-AD1 and TGR-63, have shown their ability to reduce the brain plaques associated with memory loss in Alzheimer’s in mice.

With further successful trials and FDA approvals, IGC hopes to bring TGR-63 as a treatment for Alzheimer’s disease to market.

Market Opportunity

Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. Over 70% of these patients face debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021). Agitation in dementia patients can include excessive physical movement and verbal activity, restlessness, pacing, belligerence, aggression, screaming, crying, and wandering.

In 2020, the estimated healthcare costs for Alzheimer’s disease in the U.S. were $305 billion. Medicare and Medicaid covered about 70% of those costs, leaving considerable burden on patients and families. At the current rate of growth of Alzheimer’s and other dementia diagnoses, those costs are estimated to reach over $1 trillion by 2050.

Currently, there are no FDA-approved medications to alleviate the symptoms of dementia due to Alzheimer’s disease, providing a tremendous opportunity for formulations that can have an impact on quality of life and disease progression.

Management Team

Richard Prins has been chairman at IGC since 2012 and served as an independent director since 2007. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated. Prins served in a consulting role to RBC until January 2009. He currently volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals Inc. He holds a bachelor’s degree from Colgate University and an MBA from Oral Roberts University.

Ram Mukunda is CEO and President of IGC. He has been the chief inventor and architect of most of the company’s patent filings and is responsible for the company’s strategic positioning. Prior to IGC, he was founder and CEO of Startec Global Communications, which he took public in 1997. He served as Strategic Planning Advisor at Intelsat, a communications satellite services provider. From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. He was named the 1998 Ernst & Young Entrepreneur of the Year. He holds bachelor’s degrees in electrical engineering and mathematics, and a master’s degree in engineering from the University of Maryland.

Dr. Jagadeesh Rao is the company’s Principal Scientist. His career spans two decades in the public sector and product R&D for Johnson & Johnson. He leads IGC’s scientists in the development of pharmaceutical and OTC products. He worked for the federal National Institutes of Health, and for the National Institute on Drug Abuse. His Ph.D. in Neurochemistry is from the National Institute of Mental Health & Neurosciences in India. He did postdoctoral training at the University of Illinois-Chicago.

Claudia Grimaldi is a Director, Vice President, Principal Financial Officer, and Chief Compliance Officer for IGC. She also serves as a Director/Manager Director for some of the company’s subsidiaries. She graduated with highest honors from Javeriana University in Colombia with a bachelor’s degree in psychology. She holds an MBA, graduating with highest honors, from Meredith College in North Carolina. In addition, she has attended the Darden School of Business Financial Management Executives program and the Corporate Governance Program at Columbia Business School. She is currently pursuing her Directorship Certification with the National Association of Corporate Directors. She is fluent in both English and Spanish.

IGC Pharma Inc. (NYSE American: IGC), closed Tuesday's trading session at $0.2955, off by 0.269997%, on 108,697 volume. The average volume for the last 3 months is 105,992 and the stock's 52-week low/high is $0.2785/$0.8432.

Recent News

Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF)

The QualityStocks Daily Newsletter would like to spotlight Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF).

As more and more consumers choose to curb their environmental input and governments prioritize decarbonization in a bid to fight climate change, the electric vehicle industry is gaining momentum; this achievement owes much to the progress made in critical minerals

Graphene, a form of graphite that is just one atom thick, emerges as a wonder material with a wide range of potential uses; it is being explored as a potential replacement for traditional Li-ion batteries

Poised to produce a critical mineral in America for American customers, Reflex aims to re-activate previous supply of graphite and has recently also made a strategic investment into BGS, a graphene cleantech producer, to leverage complimentary fit to its supply chain solution goals

In line with the rapid expansion of the electric vehicle ("EV") industry, the demand for battery production is experiencing rapid growth, with over five terawatt hours ("TWh") per year of gigafactory capacity expected globally by 2030 (https://ibn.fm/smgqT). A sector that has paved the way for this success story over the past years is the critical minerals industry. Here, graphite, a key component in lithium-ion batteries that power most of today's EVs, attracts much attention as consumers adopt electric vehicles and governments design policies to reduce carbon emissions. "With the supply chain that really hasn't started yet, you think of all these gigafactories, all these big companies that are announcing these big, big plans to have terawatt-sized businesses, which is fantastic. We like shiny things and getting involved with this stuff, but where are these critical elements coming from?" said Paul Gorman, CEO and Director, Reflex Advanced Materials (CSE: RFLX) (OTCQB: RFLXF), a mineral exploration company based in British Columbia, as he explained the main industry challenges in a recent interview during Benchmark Mineral Intelligence's World Tour Toronto 2023 (https://ibn.fm/BPVpn). Reflex Advanced Materials (CSE: RFLX) (OTCQB: RFLXF) (FSE: HF2) CEO and director Paul Gorman is spotlighted in the most recent episode of the Bell2Bell Podcast, which delivers insightful updates and exclusive interviews with executives operating in fast-moving industries; the podcast is sponsored by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. Reflex is a mineral exploration company based in British Columbia. During the interview, Gorman and host Stuart Smith discussed the company's business model and operating markets. "Reflex was really designed by a capital markets group taking a look at what was happening in North America pertaining to electrification," said Reflex Advanced Materials CEO and director Paul Gorman during the podcast. "Whether you look at EVs or battery storage, there is a shift, and we wanted to be part of that. So this capital markets group put together a very strong business plan and looked to put in a very strategic asset, the Ruby Graphite Mine located in southwest Montana. The reason that is very important is because, currently, there's absolutely no graphite production in the United States, and it's been that way for over 60 years. . . .  The leadership team at Reflex has positioned the company to take advantage of the looming global graphite shortage that we're seeing not only in the U.S. but in the pan-Pacific region and in Europe. The Reflex advantage is really built around domestic production and domestic purification of graphite to serve North America-based high-tech customers in need of new chemistries."

To view the full press release, visit https://ibn.fm/jkFla

Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF) is a strategic minerals company focused on locating and developing economic properties in the strategic metals and advanced materials space. The company aims to improve domestic specialty mineral infrastructure efficiencies to meet surging national demand from North American manufacturers, effectively positioning itself as one of the only North American suppliers of high purity natural graphite for hi-tech applications.

Reflex Advanced Materials is based in Vancouver, British Columbia. Its project portfolio includes the Ruby Graphite Deposit in Montana and the ZigZag Lithium Property in Ontario.

Projects

Ruby Graphite Project

Located in a mining-friendly jurisdiction in southwest Montana, the Ruby Graphite Deposit is a low cost, rapid re-entry opportunity that produced roughly 2,400 tons of graphite from 1902 to 1948. Reflex Advanced Materials holds mining rights for 755 hectares at the Ruby Graphite Project, with 96 federal lode mining claims. Recent samples assay at 95.8% to 98.4% total carbon.

The site is notable as the only combined U.S. graphite flake and vein graphite source. Vein graphite is ideal for energy storage applications, because it requires fewer steps to achieve purity than synthetic alternatives and is therefore far less environmentally damaging. This is expected to play a key role in the project’s development as demand for electric vehicles continues to surge.

In March 2023, the company announced its submittal of permit applications to the Bureau of Land Management in respect of its exploration of the Ruby Graphite Project. Its initial drill program, expected to take place in the summer of 2023, includes plans for 3,500 total meters of drilling, cored to an average depth of 130 meters. The targets for this drill program have been identified using historical data from original mine operations and data gathered for the initial 43-101 technical report on the project, dated January 31, 2023.

ZigZag Lithium Property

Located in the Thunder Bay Mining Division of Ontario, the ZigZag Lithium Property consists of eight mining claims spanning roughly 2,710 hectares. Mineralization at the property, most notably lithium, is based in pegmatite dikes and concentrated in spodumene crystals, which are consistent throughout the entire unit.

Spodumene is readily observable in outcrops and in drill cores, with crystal sizes ranging from 3-15cm, on average.

Reflex Advanced Materials and American Energy Technologies Company Metallurgical Partnership

Reflex Advanced Materials has entered into a material processing agreement with American Energy Technologies Co., which is based in Arlington Heights, Illinois, to conduct metallurgical testwork with the goal of creating a technical support data package for Reflex’s target customer base, U.S. Federal agencies and qualification programs with hi-tech customers in the battery and battery storage business.

The resulting coated, spherionized, purified graphite (CSPG) material that is expected to be created from the aforementioned tests will be used to provide potential customers of CSPG with samples so that they can begin the material qualification process.

Market Opportunity

Graphite is an ideal battery anode and has dominated the market since the proliferation of lithium-ion batteries. Despite this demand, there is currently no significant production of lithium-ion battery anode material in North America.

Instead, most graphite sold in North America today is sourced from Chinese producers. U.S. President Joe Biden highlighted this sourcing disparity in a 2022 address:

“The United Stated depends on unreliable foreign sources for many of the strategic and critical materials necessary for the clean energy transition – such as lithium, nickel, cobalt, graphite and manganese for large-capacity batteries,” he said. “Demand for such materials is projected to increase exponentially as the world transitions to a clean energy economy.”

The U.S. Department of Energy is in the process of awarding $2.8 billion to expand domestic manufacturing of batteries for electric vehicles and combat this foreign dependency. Reflex Advanced Materials has identified its Ruby Graphite Project as a prime candidate for U.S.-sponsored initiatives due to the rarity and scarcity of natural graphite deposits in the country.

Processing graphite domestically in the U.S. is expected to provide Reflex Advanced Materials a competitive advantage as manufacturers begin to seek out American supply in the face of increased diplomatic tension. This is critical, as a rise in anode demand is expected to fuel a shortage of 8 million tonnes of graphite by 2040. World Bank Group projects 494% growth in total graphite demand by 2050.

Leadership Team

Paul Gorman is the CEO and a Director of Reflex Advanced Materials. He brings to the company over 25 years of experience in junior mining finance, public listings, viability assessment and operational rationalization. For 18 years, Mr. Gorman served as president and managing partner of Riverbank Capital, where he played an instrumental role in raising more than $85 million for small-cap companies. In 2008, he funded Industrial Minerals Inc. (later Northern Graphite) and served in an advisory role for four other graphite companies, contributing significantly to the revitalization of the junior graphite space in North America. Mr. Gorman founded Mega Graphite Inc. in 2009 and has served as chief executive for three other companies.

Tasheel Jeerh, CPA, is the company’s CFO. He is a finance and accounting professional with over a decade of experience spanning both public and private sectors. Prior to joining Reflex Advanced Materials, Mr. Jeerh played a pivotal role in the growth of a private upstream oil and gas firm, dealing with over $2 billion in M&A activity and $1 billion in financing activities. He gained his designation at PricewaterhouseCoopers, where he worked as a manager in the assurance practice.

Greg Bell is Project Manager for Reflex Advanced Materials. He is a multi-disciplined engineering management professional with more than 40 years of experience in the natural resources sector. Mr. Bell has successfully built and managed several start-up operations in various capacities. He has been active in graphite and lithium exploration for the past seven years.

Christopher W. Hill leads the company’s Corporate Development initiatives. He is an investor and entrepreneur with over a decade of experience in the capital markets. Mr. Hill began his career as an investment advisor and then began to consult and advise private companies on their paths to becoming publicly traded. He specializes in corporate development and strategic financing utilizing his large network in the capital markets.

Reflex Advanced Materials Corp. (RFLXF), closed Tuesday's trading session at $0.225, off by 12.6553%, on 171,503 volume. The average volume for the last 3 months is 171,503 and the stock's 52-week low/high is $0.15/$0.765.

Recent News

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF)

The QualityStocks Daily Newsletter would like to spotlight FuelPositive Corp. (NHHHF).

FuelPositive Corporation (TSX.V: NHHH) (OTCQB:NHHHF) (the "Company"), a leading Green Ammonia company, is pleased to announce its upcoming non-brokered private placement (the "Offering") to raise up to $7,500,000. The Offering supports FuelPositive's unwavering commitment to revolutionizing the Green Ammonia industry by commercializing its sustainable solutions.

The Offering will consist of up to 115,384,615 units of the Company (each, a "Unit") priced at $0.065 per Unit. Each Unit will consist of one common share of the Company and one common share purchase warrant (each, a "Warrant"), allowing holders to purchase an additional common share at an exercise price of $0.09 within thirty-six months following the closing date of the Offering. In the event the volume-weighted average closing price of the Company's common shares on the TSX Venture Exchange exceeds $0.40 for ten consecutive trading days, the Company retains the option to accelerate the expiry date of the Warrants to thirty days after a public announcement of the election.

Ian Clifford, Board Chair and CEO, expressed his support for the Offering, stating, "We are introducing this financing to incorporate the newly implemented 'Listed Issuer Financing Exemption' (LIFE). I am often asked how non-accredited investors can participate in FuelPositive financings, and I am pleased that the LIFE structure enables new and existing shareholders, who may not qualify as accredited investors, to participate equally. Additionally, we anticipate that the enhanced liquidity resulting from this Offering will contribute to greater growth for the Company. The Company's pioneering green ammonia technology and decentralized business model holds immense potential to reshape the ammonia industry, fostering a greener future for generations to come. The net proceeds from this financing will help ensure FuelPositive's leadership and "first-mover" position in the multi-billion dollar sustainable and green ammonia industry."

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF) is a growth stage company focused on licensing, partnership and acquisition opportunities building upon various technological achievements. The company is committed to providing commercially viable and sustainable clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications.

FuelPositive is headquartered in Toronto, Canada.

Hydrogen Economy Problems and FuelPositive’s Carbon-Free Technology

The hydrogen economy is currently facing many challenges. Traditional NH3 manufacturing exists on a massive scale, but centralized facilities result in some of the world’s most concentrated CO2 emissions. In total, an estimated 200 million metric tonnes of NH3 are consumed each year, with greater than 80% utilized by the agricultural sector. NH3 is also being positioned as a viable alternative to fossil fuels.

FuelPositive’s flagship carbon-free ammonia technology provides an innovative solution to these environmental concerns. Developed by Dr. Ibrahim Dincer and his team, the company’s platform allows for the in-situ production of NH3 in an entirely sustainable manner, using only water, air and sustainable electricity.

The production of hydrogen is energy intensive, but it is just one variable hindering the growth of the hydrogen economy. Other hurdles include:

  • Storage – The storage of hydrogen by compression or liquification are both cost prohibitive and unsustainable.
  • Distribution – The distribution network for effective hydrogen deployment has yet to be developed, as the extreme high-pressure distribution requirements to transport hydrogen would result in enormous infrastructure costs.
  • End Use – R&D on the transportation-related end use applications for hydrogen is in its infancy, but almost any vehicle on the road today can be easily converted to run on NH3 at a considerably lower cost per mile traveled when compared to traditional fossil fuels.

A key benefit of FuelPositive’s patent-pending, first-of-its-kind carbon-free NH3 technology is its flexibility. The process allows for small, medium or large-scale production of NH3 on location, minimizing or even eliminating the challenges and volatility associated with storage and transportation to end use. As such, with an appropriately sized FuelPositive system and access to renewable energy, the end use applications for the company’s platform are nearly infinite.

Manufacturing Partnership

On May 19, 2021, FuelPositive announced its selection of National Compressed Air Canada Ltd. (“NCA”) to undertake manufacturing of the company’s Phase 2 hydrogen-ammonia synthesizer commercial prototype systems for carbon-free ammonia production.

In a news release detailing the partnership, FuelPositive CEO Ian Clifford noted, “This critical milestone for FuelPositive will confirm the broad application potential for our technology and is the backbone of our Carbon-Free Hydrogen-NH3 offering. Partnering with the knowledgeable and experienced team at NCA on this commercialization project will bring our development-stage program to life.”

Global Ammonia Market Outlook

The global ammonia market was valued at $52.71 billion in 2017 and is forecast to reach $81.42 billion by 2025, growing at a CAGR of 5.59%, according to data from Fior Markets (https://ibn.fm/1OfOB).

The agricultural industry consumes more than 80% of global NH3. Smaller percentages can be attributed to the waste, water treatment, refrigerants, antiseptic, textile, mining and pharmaceutical industries.

One of the most polluting industries on the planet consists of conventional agribusinesses. These polluters are responsible for more greenhouse emissions per year than transportation. This is where FuelPositive’s technology is expected to be extremely beneficial.

Management Team

Ian Clifford is Director, CEO and Founder of FuelPositive Corp. He has over 25 years of experience in the fields of technology and marketing and has successfully led the company to global brand recognition through its unique energy solutions. Since 2006, Mr. Clifford has raised over $50 million in equity financing for FuelPositive. He also co-founded digIT Interactive, a full-service internet marketing company serving Fortune 500 clients, which he sold at the peak of the market in 2000.

Greg Gooch serves as a Director and President of FuelPositive. His multifaceted career in the electronics and finance industries has positioned him as a key advisor and funding partner to start-ups and new technology companies for over 40 years. Mr. Gooch has been involved with FuelPositive since its early days and has remained a significant supporter and consultant to the company over the years. He has a bachelor’s from McGill University and an MBA from the University of Western Ontario.

Dr. Ibrahim Dincer is a scientific advisor to FuelPositive and is recognized as a pioneer and international leader in the area of sustainable energy technologies. Along with his team, Dr. Dincer invented the modular carbon-free ammonia (NH3) production technology that FuelPositive is commercializing. His area of specialty covers various topics including ammonia, hydrogen energy and fuel cells; renewable energy systems; energy storage systems and applications; carbon capturing technologies, and integrated and hybrid energy systems He is currently managing an exemplary team of researchers in this commercialization project.

Marek Warunkiewicz is the company’s Communications & Branding Specialist. He brings more than 40 years of entrepreneurial expertise to the FuelPositive team, having held marketing, branding, advertising, project management and graphic design positions with various companies. Mr. Warunkiewicz has successfully created business-to-business marketing and advertising campaigns for a diverse group of clients ranging from high-tech to agriculture. He co-founded digIT Interactive and ZENN Motor Company alongside Ian Clifford.

Luna Clifford is the Director of Communications for FuelPositive. She has over 10 years of experience as a business owner and advisor, helping build and operate several successful start-up enterprises while managing complex stakeholder relationships. Ms. Clifford excels in strategic planning and team building, and she has completed extensive studies in the fields of communications and health care.

FuelPositive Corp. (NHHHF), closed Tuesday's trading session at $0.102, up 2%, on 583,560 volume. The average volume for the last 3 months is 583,560 and the stock's 52-week low/high is $0.051/$0.17.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.